GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (OSTO:DMYD B) » Definitions » EBITDA Margin %

Diamyd Medical AB (OSTO:DMYD B) EBITDA Margin % : 0.00% (As of May. 2025)


View and export this data going back to 2013. Start your Free Trial

What is Diamyd Medical AB EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Diamyd Medical AB's EBITDA for the three months ended in May. 2025 was kr-41.39 Mil. Diamyd Medical AB's Revenue for the three months ended in May. 2025 was kr0.00 Mil. Therefore, Diamyd Medical AB's EBITDA margin for the quarter that ended in May. 2025 was 0.00%.


Diamyd Medical AB EBITDA Margin % Historical Data

The historical data trend for Diamyd Medical AB's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diamyd Medical AB EBITDA Margin % Chart

Diamyd Medical AB Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
EBITDA Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3,046.33 24,221.34 -21,779.74 -20,366.48 -108,346.92

Diamyd Medical AB Quarterly Data
Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -74,273.08 -236,494.74 -128,044.00 -49,939.53 -

Competitive Comparison of Diamyd Medical AB's EBITDA Margin %

For the Biotechnology subindustry, Diamyd Medical AB's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diamyd Medical AB's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Diamyd Medical AB's EBITDA Margin % falls into.


;
;

Diamyd Medical AB EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Diamyd Medical AB's EBITDA Margin % for the fiscal year that ended in Aug. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Aug. 2024 )/Revenue (A: Aug. 2024 )
=-140.851/0.13
=-108,346.92 %

Diamyd Medical AB's EBITDA Margin % for the quarter that ended in May. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: May. 2025 )/Revenue (Q: May. 2025 )
=-41.393/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Diamyd Medical AB  (OSTO:DMYD B) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


Diamyd Medical AB EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Diamyd Medical AB's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Diamyd Medical AB Business Description

Traded in Other Exchanges
Address
Kungsgatan 29, Stockholm, SWE, SE-111 56
Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.

Diamyd Medical AB Headlines

No Headlines